Z
Zylö Therapeutics
Offers an innovative sustained-release drug-delivery system
About Zylö Therapeutics
Zylö Therapeutics, established in 2017, is a life sciences company commercializing a topical drug delivery platform. The firm was founded by Scott Pancoast, who serves as CEO and brings extensive experience from the venture capital and biotech sectors, having previously led a company from incubation to a NASDAQ listing. Pancoast, an MBA from Harvard Business School, was joined by a team that includes scientific co-founders from the Albert Einstein College of Medicine, where the core technology was originally licensed.
The company's core offering is its patented Z-pod® technology, a topical delivery system using silica-derived microparticles to encapsulate active ingredients. This platform is designed to provide sustained, controlled release of therapeutic or cosmetic agents for over 24 hours, enhancing their bioavailability and duration of effect compared to traditional topical applications. Zylö refers to this as a "Patchless Patch™" concept, where the Z-pod® particles are integrated into standard creams or gels, embed in the outer layers of the skin, and gradually release their payload before naturally sloughing off. The particles can be manufactured at their Greenville, South Carolina facility and milled to various sizes to suit different formulations.
Zylö Therapeutics operates on a business-to-business model, primarily forging partnerships with companies in the pharmaceutical, cosmetic, and animal health industries. The company does not manufacture final consumer products but rather supplies its Z-pod® technology as a key ingredient, marketed with a 'Powered by Z-pod®' branding akin to 'Intel Inside'. This strategy has led to collaborations, such as the one with BosleyMD for a hair regrowth product line that incorporates the Z-pod® technology to deliver a proprietary active ingredient. Due to the broad applicability of its platform, Zylö spun out a new entity, Atticus Pharma, in 2024 to focus specifically on pharmaceutical applications, including treatments for alopecia and wound healing, while Zylö continues to serve the cosmetics and animal health markets.
The company has successfully secured funding through multiple rounds, including a $4 million Series A in 2019 and an oversubscribed $5.225 million Series B in 2022, with participation from investors like VentureSouth, New York Angels, and SC Launch. These funds have been allocated to scaling up the manufacturing of Z-pods®, implementing quality control systems like cGMP, and advancing internal research projects. The company has also received numerous government grants from the NIH for research into applications for conditions such as erectile dysfunction, cutaneous lupus, and onychomycosis.
Source: Dealroom company dataNews
Open roles
Zylö Therapeutics in the Greenville ecosystem
The Zylö Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
South Carolina Research Authority
VentureSouth
National Institute of Diabetes and Digestive and Kidney Diseases
Series A7 investors entered at this stage
- APAriel Southeast Angel Partners
Chemical Angel Network
New York Angels
Boston Harbor Angels- JCJames Cordes
HBS Alumni Angels of Greater New York
Cowtown Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zylö Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zylö Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


